CLINICAL_TRIALS
trial_result
· 2012-03-06
Clinical Trial Update: Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease [Phase 3]
Summary
A Phase III randomized study evaluating Poloxamer 188 for vaso-occlusive crisis in sickle cell disease has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Mast Therapeutics, Inc. | Conditions: Sickle Cell Anemia | Phase 3 | Status: COMPLETED